As of May 26
| +0.16 / +0.50%|
The 15 analysts offering 12-month price forecasts for Beam Therapeutics Inc have a median target of 66.00, with a high estimate of 105.00 and a low estimate of 37.00. The median estimate represents a +103.89% increase from the last price of 32.37.
The current consensus among 16 polled investment analysts is to Buy stock in Beam Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.